We are live on ! Find out more
FCMV

Foresite Capital Management VI Portfolio holdings

AUM $460M
1-Year Est. Return 261.77%
This Fund
S&P 500
This Quarter Est. Return
+60.46%
1 Year Est. Return
+261.77%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$460M
AUM Growth
+$129M
Cap. Flow
-$7.38M
Cap. Flow %
-1.6%
Top 10 Hldgs %
90.54%
Holding
19
New
7
Increased
4
Reduced
1
Closed
2

Top Buys

Rank Stock Value
1
NERV icon
Minerva Neurosciences
NERV
+$11.4M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.47M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.61M
4
CRVS icon
Corvus Pharmaceuticals
CRVS
+$7.18M
5
GHRS icon
GH Research
GHRS
+$4.84M

Top Sells

Rank Stock Value
1
RAPT
RAPT Therapeutics
RAPT
+$52.9M
2
NTRA icon
Natera
NTRA
+$15.4M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$142K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGON icon
1
CG Oncology
CGON
$6.37B
$150M 32.67%
2,221,474
– –
ALMS
2
Alumis Inc
ALMS
$3.41B
$93.6M 20.33%
4,247,670
– –
CNTA
3
DELISTED
Centessa Pharmaceuticals
CNTA
$54.2M 11.77%
1,364,019
– –
CRVS icon
4
Corvus Pharmaceuticals
CRVS
$1.08B
$26.8M 5.82%
1,831,233
+450,000
+33% +$7.18M
DNLI icon
5
Denali Therapeutics
DNLI
$3.76B
$23.2M 5.05%
1,209,971
+209,971
+21% +$4.18M
AGIO icon
6
Agios Pharmaceuticals
AGIO
$2.15B
$17.8M 3.86%
525,000
-5,000
-0.9% -$142K
VSTM icon
7
Verastem
VSTM
$540M
$16.7M 3.62%
3,146,631
+11,511
+0.4% +$71K
KYMR icon
8
Kymera Therapeutics
KYMR
$8.81B
$12.2M 2.65%
146,332
– –
NERV icon
9
Minerva Neurosciences
NERV
$195M
$12M 2.6%
+1,986,600
New +$11.4M
CLDX icon
10
Celldex Therapeutics
CLDX
$2.78B
$10M 2.18%
+315,913
New +$8.61M
ATAI icon
11
AtaiBeckley Inc
ATAI
$2.65B
$9.73M 2.12%
2,750,000
– –
HNGE
12
Hinge Health
HNGE
$5.75B
$8.5M 1.85%
220,400
+85,400
+63% +$3.55M
CRNX icon
13
Crinetics Pharmaceuticals
CRNX
$8.88B
$7.7M 1.67%
+212,010
New +$9.47M
OKUR
14
OnKure Therapeutics
OKUR
$159M
$5.99M 1.3%
+1,445,783
New +$4.46M
JBIO
15
Jade Biosciences
JBIO
$1.15B
$4.5M 0.98%
+320,000
New +$4.63M
GHRS icon
16
GH Research
GHRS
$1.86B
$4.44M 0.96%
+315,492
New +$4.84M
ZURA icon
17
Zura Bio
ZURA
$511M
$2.68M 0.58%
+450,000
New +$2.72M
NTRA icon
18
Natera
NTRA
$36.7B
– –
-67,356
Closed -$15.4M
RAPT
19
DELISTED
RAPT Therapeutics
RAPT
– –
-1,562,500
Closed -$52.9M

Similar funds

MCB
Morton Community Bank East Peoria, Illinois $460M AUM 17.72% 1-Year Est. Return
WCM
Weaver Capital Management Suwanee, Georgia $461M AUM 20.77% 1-Year Est. Return
PC
Pureheart Capital Singapore $459M AUM 23.59% 1-Year Est. Return
PIN
Prudent Investors Network Lake Forest, California $459M AUM 9.48% 1-Year Est. Return
FCG
Fielder Capital Group Nashville, Tennessee $459M AUM 48.94% 1-Year Est. Return
GLAM
Gardner Lewis Asset Management Chadds Ford, Pennsylvania $462M AUM 65.29% 1-Year Est. Return
PRCP
Pacific Ridge Capital Partners Lake Oswego, Oregon $462M AUM 40.76% 1-Year Est. Return
AC
Aristides Capital Louisville, Kentucky $462M AUM 28.94% 1-Year Est. Return

Foresite Capital Management VI's Q1 2026 Portfolio in Review

As of Q1 2026, Foresite Capital Management VI held 19 positions worth $460M, up 39% from $331M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Foresite Capital Management VI's Q1 2026 filing shows 7 new, 4 increased, 1 reduced and 2 closed positions. Its largest new stake was Minerva Neurosciences: 1,986,600 shares worth $12M. The largest sale was RAPT Therapeutics, an estimated $52.9M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Foresite Capital Management VI's largest Q1 2026 buy was Minerva Neurosciences: 1,986,600 shares worth $12M.
  • Foresite Capital Management VI added most to Corvus Pharmaceuticals in Q1 2026, an estimated $7.18M increase.
  • Foresite Capital Management VI's biggest Q1 2026 reduction was Agios Pharmaceuticals, cutting an estimated $142K.
  • Foresite Capital Management VI fully exited RAPT Therapeutics in Q1 2026, selling an estimated $52.9M.
  • Foresite Capital Management VI's ten largest holdings make up 91% of its $460M portfolio in Q1 2026.
  • Foresite Capital Management VI opened 7 new positions and closed 2 in Q1 2026.
  • Foresite Capital Management VI's portfolio value rose 39% quarter-over-quarter to $460M.

Based on Foresite Capital Management VI's 13F filing for Q1 2026, filed 15 May 2026.